Evidence map›Paper›PMID 26353754›Full record

ArticleBMC cancer2015

S100A16 promotes differentiation and contributes to a less aggressive tumor phenotype in oral squamous cell carcinoma.

Dipak Sapkota, Ove Bruland, Himalaya Parajuli, Tarig A Osman, Muy-Teck Teh, Anne C Johannessen, Daniela Elena Costea

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. RAGE Inhibitors for Targeted Therapy of Cancer: A Comprehensive Review.International journal of molecular sciences · 2022
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Dipak SapkotaDepartment of Clinical Medicine, The Gade Laboratory for Pathology, University of Bergen, Haukeland University Hospital, N-5021, Bergen, Norway. Dipak.Sapkota@k1.uib.no.
Ove BrulandCenter of Medical Genetics and Molecular Medicine, Haukeland University Hospital, University of Bergen, N-5021, Bergen, Norway. ove.bruland@helse-bergen.no.
Himalaya ParajuliDepartment of Clinical Medicine, The Gade Laboratory for Pathology, University of Bergen, Haukeland University Hospital, N-5021, Bergen, Norway. Himalaya.Parajuli@k1.uib.no.
Tarig A OsmanDepartment of Clinical Medicine, The Gade Laboratory for Pathology, University of Bergen, Haukeland University Hospital, N-5021, Bergen, Norway. Tarig.Osman@k1.uib.no.
Muy-Teck TehCentre for Clinical and Diagnostic Oral Sciences, Institute of Dentistry, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, England, UK. m.t.teh@qmul.ac.uk.
Anne C JohannessenDepartment of Clinical Medicine, The Gade Laboratory for Pathology, University of Bergen, Haukeland University Hospital, N-5021, Bergen, Norway. Anne.Johannessen@k1.uib.no.
Daniela Elena CosteaDepartment of Clinical Medicine, The Gade Laboratory for Pathology, University of Bergen, Haukeland University Hospital, N-5021, Bergen, Norway. Daniela.Costea@k1.uib.no.
University of Bergen · NOHaukeland University Hospital · NOQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAltered expression of S100A16 has been reported in human cancers, but its biological role in tumorigenesis is not fully understood. This study aimed to investigate the clinical significance and functional role of S100A16 in oral squamous cell carcinoma (OSCC) suppression.

methodsS100A16 mRNA and/or protein levels were examined by quantitative RT-PCR and immunohistochemistry in whole- and laser microdissected-specimens of normal human oral mucosa (NHOM, n = 65), oral dysplastic lesions (ODL, n = 21), OSCCs (n = 132) and positive cervical nodes (n = 17). S100A16 protein expression in OSCC was examined for correlations with clinicopathological variables and patient survival. S100A16 was over-expressed and knocked-down in OSCC-derived (CaLH3 and H357) cells by employing retroviral constructs to investigate its effects on cell proliferation, sphere formation and three dimensional (3D)-organotypic invasive abilities in vitro and tumorigenesis in a mouse xenograft model.

resultsBoth S100A16 mRNA and protein levels were found to be progressively down-regulated from NHOM to ODL and OSCC. Low S100A16 protein levels in OSCC significantly correlated with reduced 10-year overall survival and poor tumor differentiation. Analysis of two external OSCC microarray datasets showed a positive correlation between the mRNA expression levels of S100A16 and keratinocyte differentiation markers. CaLH3 and H357 cell fractions enriched for differentiated cells either by lack of adherence to collagen IV or FACS sorting for low p75NTR expression expressed significantly higher S100A16 mRNA levels than the subpopulations enriched for less differentiated cells. Corroborating these findings, retroviral mediated S100A16 over-expression and knock-down in CaLH3 and H357 cells led to respective up- and down-regulation of differentiation markers. In vitro functional studies showed significant reduction in cell proliferation, sphere formation and 3D-invasive abilities of CaLH3 and H357 cells upon S100A16 over-expression. These functional effects were associated with concomitant down-regulation of self-renewal (Bmi-1 and Oct 4A) and invasion related (MMP1 and MMP9) molecules. S100A16 over-expression also suppressed tumorigenesis of H357 cells in a mouse xenograft model and the resulting tumor xenografts displayed features/expression of increased differentiation and reduced proliferation/self-renewal.

conclusionsThese results indicate that S100A16 is a differentiation promoting protein and might function as a tumor suppressor in OSCC.

Indexed as

PhenotypeAdultAgedAged, 80 and overAnimalsBiopsyCarcinoma, Squamous CellCell ProliferationFemaleGenetic VectorsHeterograftsHumansMaleMiceMiddle AgedModels, AnimalS100A16 protein, humanS100 Proteins

Identifiers

PMID26353754
PMCPMC4564982
OpenAlexW1851468002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.